Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157383 | 0.88 | FDPS (0.35) | GRNSORT1CYP2D6NR3C2LNPEP | |
| SCHEMBL10223946 | 0.84 | ESR1 (0.40) | GRNSORT1LMNANR3C2LNPEP | |
| SCHEMBL22905302 | 0.82 | FDPS (0.41) | TAAR1LMNACYP2D6HTTSMN1; SMN2 | |
| SCHEMBL22762224 | 0.80 | CYP2D6 (0.41) | SLC6A2CYP2D6 | |
| SCHEMBL18924303 | 0.77 | KDM4E (0.41) | LMNALNPEPNOS2 | |
| SCHEMBL11926806 | 0.77 | NOS3 (0.52) | GRNSORT1LMNATRPA1LNPEP | |
| SCHEMBL21533986 | 0.76 | NOS3 (0.35) | LMNANR3C2LNPEPNOS2 | |
| SCHEMBL1572105 | 0.75 | SLC6A2 (0.64) | SLC6A2TAAR1LMNACYP2D6TRPA1 | |
| SCHEMBL12561686 | 0.75 | RECQL (0.50) | GRNSORT1LMNANR3C2LNPEP | |
| SCHEMBL18714374 | 0.75 | L3MBTL1 (0.45) | TAAR1LMNACYP2D6HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132484-A1 | STERICALLY HINDERED PHOSPHINE-AMIDE SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | PCNA, NIT2, MCM7 | GRN 1344/4885SORT1 4107/4885SLC6A2 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.